![](images/graphics/blank.gif)
Antibody therapy
-
For patients with locally advanced rectal cancer (LARC), total neoadjuvant therapy (TNT), namely, intensifying preoperative treatment through the integration of radiotherapy and systemic chemotherapy before surgery, was commonly recommended as the standard treatment.
10p
vishanshan
27-06-2024
1
1
Download
-
Paclitaxel is commonly used as a second-line therapy for advanced gastric cancer (AGC). The decision to proceed with second-line chemotherapy and select an appropriate regimen is critical for vulnerable patients with AGC progressing after first-line chemotherapy.
9p
vishanshan
27-06-2024
2
1
Download
-
A new class of antibody-based drug therapy with the potential for disease modification is now available for Alzheimer’s disease (AD). However, the complexity of drug eligibility, administration, cost, and safety of such disease modifying therapies (DMTs) necessitates adopting new treatment and care pathways.
12p
vishanshan
27-06-2024
2
1
Download
-
Novel antibody-drug conjugates (ADCs) drugs present a promising anti-cancer treatment, although survival benefits for HER2-positive advanced breast cancer (BC) remain controversial. The aim of this meta-analysis was to evaluate the comparative effect of ADCs and other anti-HER2 therapy on progression-free survival (PFS) and overall survival (OS) for treatment of HER2-positive locally advanced or metastatic BC.
10p
vikoch
27-06-2024
1
1
Download
-
Despite the utilization of immune checkpoint inhibitors (ICIs) in treating numerous types of cancers being approved, their efficacy in tumor control in the clinic is not satisfactory. Since adoptive cell therapy (ACT) can alter the tumor microenvironment, we hypothesized that ACT potentially synergized with ICI in tumor control and examined this hypothesis via a murine allograft model.
11p
vikoch
27-06-2024
1
1
Download
-
Ebook "Targeted therapies in cancer: Myth or Reality?" contributes to improve our approach to cancer drug discovery and, ultimately, to find new, more efficacious and better tolerated drugs for cancer patients. It provides an overview of diverse approaches ranging from drug discovery to cellular therapy. Although this change in paradigm has been useful, its entry into the clinical arena was associates with unforeseen problems including the emergence of resistance, unexpected side effects and failures.
200p
ladongphongthanh1008
22-04-2024
7
1
Download
-
Bevacizumab, a monoclonal antibody against soluble VEGFA, is an approved and commonly administered anti-angiogenic drug in patients with metastasized colorectal cancer (mCRC). The survival benefit of anti-VEGF therapy in mCRC patients is limited to a few months, and acquired resistance mechanisms are largely unknown.
17p
vibransone
28-03-2024
3
2
Download
-
Targeted therapies such as kinase inhibitors and monoclonal antibodies have dramatically altered cancer care in recent decades. Although these targeted therapies have improved patient outcomes in several cancer types, resistance ultimately develops to these agents.
12p
vioraclene
31-03-2024
5
2
Download
-
Ebola virus disease (EVD) is an often-fatal infection where the effectiveness of medical countermeasures is uncertain. During the West African outbreak (2013–2016), several patients were treated with different types of antiviral therapies including monoclonal antibody-based cocktails that had the potential to neutralise Ebola virus (EBOV). However, at the time, the efficacy of these therapies was uncertain.
18p
vibransone
28-03-2024
5
2
Download
-
The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in CRC patient-derived xenograft (PDX) models as a strategy for a molecular dissection of SR mechanisms.
25p
vibransone
28-03-2024
3
2
Download
-
Human epidermal growth factor receptor 2 (HER2) has been identified as a molecular target for breast cancer therapy, such as Trastuzumab (Herceptin®). This has been shown to improve patient survival substantially.
10p
vibego
02-02-2024
0
0
Download
-
Opportunistic viral infections such as Cytomegalovirus (CMV), Hepatitis B (HBV) and C (HCV) are often prevalent in HIV patients undergoing antiretroviral therapy (ART) thereby shortening the life span of infected patients. The co-infection of CMV, HBV and HCV among HIV positive patients attending ART clinics across hospitals in Ekiti State, Nigeria, were studied.
11p
vikissinger
21-12-2023
5
1
Download
-
Combination chemoimmunotherapy (CIT) consisting of anti-CD20 has improved the progression-free survival (PFS) and overall survival (OS) of patients with chronic lymphocytic leukaemia (CLL). We performed a comprehensive synthesis of prognostic factors in patients with CLL on combined CIT with anti-CD20 antibodies compared with standard chemotherapy alone or targeted therapy.
17p
vileonardodavinci
23-12-2023
5
3
Download
-
HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3+or 2+with in situ hybridization (ISH) amplifcation) are treated with HER2 targeted therapies.
10p
vileonardodavinci
23-12-2023
10
4
Download
-
RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive markers for anti-epidermal growth factor receptor monoclonal antibody (antiEGFR mAb) therapy, but many tumors containing wild-type RAS genes still do not respond to these therapies.
27p
vileonardodavinci
23-12-2023
7
2
Download
-
Novel ADC drugs provide a new therapeutic strategy for gastric cancer.The present study aimed to analyze the clinical efficacy and drug toxicities of disitamab vedotin (RC48) plus immune checkpoint inhibitors(ICIs) and RC48 as third-line therapies and beyond for advanced and metastatic gastric cancer patients.
8p
vileonardodavinci
23-12-2023
3
3
Download
-
Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen.
9p
vialfrednobel
23-12-2023
7
3
Download
-
Salivary gland carcinomas (SGC) are extremely rare malignancies with only limited treatment options for the metastatic phase of the disease. Treatment with anti-CD47 antibodies could represent a potent therapy for SGCs by promoting the phagocytic clearance of tumor cells through various mechanisms.
10p
vialfrednobel
23-12-2023
6
3
Download
-
Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs (Immune Checkpoint Inhibitors). In a clinical trial, combining the anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) Mab (monoclonal antibody) tiragolumab with atezolizumab improved outcomes in non-small cell lung cancer.
15p
vialfrednobel
23-12-2023
8
4
Download
-
Autologous hematopoietic stem cell transplantation therapy has been widely used in recent decades for the treatment of hematological diseases, cancer, and autoimmune diseases. In autoimmune diseases, self-activated T lymphocytes and B lymphocytes secreting antibodies against host antigens are considered to be central in the pathogenesis of the disease.
7p
vispacex
13-11-2023
6
2
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)